Trial of Extended Release Bupivacaine for Pain Relief After Surgery
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This is a research study of SABER® -Bupivacaine, an experimental medication designed to
reduce pain for up to 3 days after surgery. Given once by the surgeon at the end of surgery,
SABER® - Bupivacaine delivers a locally-acting pain reliever directly to the surgical wound.
The purpose of this study is to measure how well it works in reducing pain after laparoscopic
cholecystectomy (surgery to remove the gall bladder) and to investigate the safety of
SABER®-Bupivacaine (its side effects).